Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 


12345678910111213...15231524»
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / AbbVie
    Journal:  Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases. (Pubmed Central) -  Jun 24, 2024   
    Mirvetuximab soravtansine is an antifolate receptor alpha monoclonal antibody, with an approved FOLR1-2.1 immunohistochemical biomarker...Significant differences in FOLR1 staining were noted between histotypes, age of the specimen, type of case tested, and site of disease tested. Further testing is needed to help determine the best tissue to be utilized for this new biomarker.
  • ||||||||||  Preclinical, Journal:  Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice. (Pubmed Central) -  Jun 24, 2024   
    The efficacy was evaluated by the tumor volume. This protocol will maximize animal protection and improve the reliability of research data, therefore providing effective strategies for future investigating therapeutic efficacy and molecular mechanisms of decoction formula for traditional Chinese medicine in vivo.
  • ||||||||||  Journal:  Additional Role of 3D ASL Perfusion in Skull Base Lesions. (Pubmed Central) -  Jun 24, 2024   
    Chordomas have variable perfusion, which helps in prognosticating the tumors. ASL benefits pediatric patients and in renal failure as well since it avoids the ethical ambiguity associated with contrast agents.
  • ||||||||||  Journal:  Acute embolic stroke secondary to prolapsing left atrial mass in a patient with synovial sarcoma. (Pubmed Central) -  Jun 24, 2024   
    In summary, this research provides insights into the complex interactions between Ce-MBGs, Poly, and various cell types in distinct 2D and 3D in vitro models, highlighting the potential of loaded Ce-MBGs for post-resection bone tissue engineering with a balance between pro-regenerative and anti-tumorigenic activities. No abstract available
  • ||||||||||  Journal:  The Role of Colon in Isolated Intestinal Transplantation: Description of 4 Cases. (Pubmed Central) -  Jun 24, 2024   
    Intestinal transplantation, either autotransplantation or allotransplantation, has been used as a viable option to treat this group of patients. Herein, we describe a series of 4 patients with unresectable intra-abdominal desmoid tumor who underwent cadaveric isolated intestinal and ascending colon transplantation.
  • ||||||||||  Journal:  Hsa_circ_0064636 regulates voltage dependent anion channel 1/ubiquitination factor E4A through miR?326/miR?503?5 in osteosarcoma. (Pubmed Central) -  Jun 24, 2024   
    Among the target genes obtained from the miR-326 and miR-503-5p screens, ubiquitination factor E4A (UBE4A) and voltage dependent anion channel 1 (VDAC1) were respectively identified to significantly affect prognosis; only miR-326 targets UBE4A and only miR-503 targets VDAC1. To conclude, these aforementioned findings suggest that hsa_circ_0064636 may be involved in the development of OS by sponging miR-503-5p and miR-326to inhibit their effects, thereby regulating the expression of VDAC1 and UBE4A.
  • ||||||||||  Journal:  Breast Metastasis From Cutaneous Melanoma: Beyond the Infiltrating Ductal Carcinoma. (Pubmed Central) -  Jun 24, 2024   
    The therapeutic approach regarding the possible origin of the metastatic neoplastic character of breast tumors culminated in this case in the palliative treatment with immunotherapy of cutaneous malignant melanoma. The diagnosis of breast metastases from cutaneous malignant melanoma is a real challenge, so an extensive history and high clinical suspicion are crucial in order to provide adequate treatment, despite the gloomy prognosis.
  • ||||||||||  Modeling Immune Evasion And Immunotherapy Response in Distant Metastases of Lung Adenocarcinoma () -  Jun 23, 2024 - Abstract #LUNGSPORE2024LUNG_SPORE_81;    
    We have also identified some potential targets like the chemokine ligand 2 (CCL2), which could be potentially targeted to enhance ICB response. These results suggested that our syngeneic models recapitulate immune evasion mechanisms observed in patients and enable the study of immune evasion and resistance to ICB in distant metastases.
  • ||||||||||  Journal, Surgery:  Function-preserving surgery in sporadic desmoid-type fibromatosis of brachial plexus. (Pubmed Central) -  Jun 23, 2024   
    A tailored multidisciplinary surgical approach, with the aim to preserve function over radiological clearance, is an acceptable treatment strategy in preserving patient's quality of life for such infiltrating desmoid tumours encasing the brachial plexus. Following surgery, observation and close radiological surveillance offer an optimal strategy without jeopardizing the quality of life.
  • ||||||||||  Review, Journal:  The basaloid-spectrum of salivary gland tumors: A focused review with practical diagnostic considerations. (Pubmed Central) -  Jun 22, 2024   
    However, salivary gland tumors with even minor basaloid components may appear 'basaloid' in small biopsy specimens and, thus, a choice was made to focus on common and uncommon diagnostic differentials with this in mind. Entities that will be covered in this review also include basal cell adenoma and basal cell adenocarcinoma, adenoid cystic carcinoma, lymphoepithelial carcinoma, sialoblastoma, adamantinoma-like Ewing Sarcoma, NUT carcinoma, and carcinoma showing thymus-like differentiation.
  • ||||||||||  carboplatin / Generic mfg., etoposide IV / Generic mfg.
    Journal:  Ewing sarcoma/primitive hepatic neuroectodermal tumor (Pubmed Central) -  Jun 22, 2024   
    The patient rejected the proposed surgical procedure. Our objective is to highlight the clinical and histological diagnostic challenge of this entity that requires ruling out other clinical entities.
  • ||||||||||  UNC2025 - University of North Carolina / Chapel Hill, MRX2843 / Meryx, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
    Journal:  Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma. (Pubmed Central) -  Jun 22, 2024   
    Excitingly, the TAM kinase inhibitor MRX-2843 currently in human clinical trials to treat AML and advanced solid tumors, enhances chemotherapy efficacy to further suppress Ewing sarcoma tumor growth in vivo. Our findings reveal an Ewing sarcoma chemoresistance mechanism with an immediate translational value.
  • ||||||||||  Journal:  Discovery of a CCR2-targeting pepducin therapy for chronic pain. (Pubmed Central) -  Jun 22, 2024   
    Importantly, PP101-induced reduction of CCR2 signaling in DRGs did not result in deleterious tumor progression or adverse behavioral effects. Thus, targeting neuroimmune crosstalk through allosteric inhibition of CCR2 could represent an effective and safe avenue for the management of chronic pain.
  • ||||||||||  Biomarker, Retrospective data, Journal:  GLI1 Co-Amplification in Well-differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases. (Pubmed Central) -  Jun 22, 2024   
    In this large-scale cohort of GLI1 co-amplified WD/DDLPS, we elucidate uniquely recurrent features including meningothelial whorls and GLI-altered morphology in dedifferentiated areas. Assessment of tumor location (retroperitoneal or mediastinal), identification of a well-differentiated liposarcoma component, and co-amplification of other spatially discrete genomic segments (1p, 6q) might aid in distinction from tumors with true driver GLI1 alterations.
  • ||||||||||  Enrollment closed, Trial completion date:  The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors (clinicaltrials.gov) -  Jun 21, 2024   
    P=N/A,  N=8, Active, not recruiting, 
    At our institution, we are in the process of developing a large prospective clinical trial for this purpose. Completed --> Active, not recruiting | Trial completion date: Aug 2023 --> Jan 2025
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
    Trial completion, Trial completion date, Trial primary completion date:  Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes (clinicaltrials.gov) -  Jun 21, 2024   
    P2,  N=56, Completed, 
    This review tentatively endorses intensified chemotherapy with G-CSF primary prophylaxis for Ewing sarcoma. Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jun 2024 | Trial primary completion date: Dec 2025 --> Jun 2024
  • ||||||||||  Journal:  Myeloid sarcoma: Experience from a tertiary care center in southern India - A series of eight unusual cases. (Pubmed Central) -  Jun 21, 2024   
    All but one case succumbed to their disease. Without adequate clinical history and appropriate use of ancillary techniques such as IHC in tissue biopsies, flow cytometry, cytogenetics, and molecular studies, these cases have a high chance of being misdiagnosed as non-Hodgkin lymphoma, small round blue cell tumor, or undifferentiated carcinomas, which can complicate patient management and prognosis.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Review, Journal:  Recurrent mucinous carcinoma with sarcomatoid and sarcomatous mural nodules: a case report and literature review. (Pubmed Central) -  Jun 21, 2024   
    The patient received a second operation and postoperative chemotherapy plus Anlotinib with no progression at 16 months of follow-up...Malignant mural nodules represent dedifferentiation in mucinous ovarian tumors rather than collision of two different tumor types. Therefore, it is imperative to conduct comprehensive sampling, rigorous clinical examination, and postoperative follow-up in order to thoroughly evaluate all mural nodules of ovarian mucinous tumors due to their potential for malignancy and sarcomatous differentiation.
  • ||||||||||  Review, Journal:  Metronomic chemotherapy: bridging theory to clinical application in canine and feline oncology. (Pubmed Central) -  Jun 21, 2024   
    This multi-targeted therapy has been described as a treatment option in several canine and feline cancers since 2007, with positive results already published in the literature, particularly in mammary carcinomas and soft tissue sarcomas in dogs. The aim of this review article is to describe the current knowledge about the use of MC in small animal oncology, with emphasis on its mechanisms of action, the most commonly used drugs and clinical outcome.
  • ||||||||||  Journal:  Rehabilitation Treatment of a Patient With Total Humeral Endoprosthetic Replacement. (Pubmed Central) -  Jun 21, 2024   
    The use of a brace and seamless rehabilitation from the acute phase to convalescence and community-based rehabilitation enabled the patient with THR to return to work. This study suggests that precise assessment of the disorders and consecutive rehabilitation treatment with a brace should be considered after THR.